The Effect of Episiotomy on Maternal and Fetal Outcomes (EPITRIAL)

February 2, 2020 updated by: Lena Sagi-Dain

The Effect of Episiotomy on Advanced Perineal Tears and Other Maternal and Fetal Outcomes - Randomized Controlled Multicentric Trial (EPITRIAL)

This study is aimed to evaluate the influence of episiotomy on various maternal and neonatal outcomes. Half of the participants will undergo selective episiotomy (according to routine delivery management at the particular hospital), while the other half will not undergo epitiotomy at all.

Our hypothesis is that no differences in maternal and neonatal outcomes will be demonstrated between these two groups.

Study Overview

Status

Terminated

Intervention / Treatment

Detailed Description

Episiotomy is one of the most prevalent surgical interventions at the delivery room, ranging in frequency from about 10% and up to 75%. The presumed benefits of this procedure include prevention of advanced (3rd and 4th degree) perineal tears, facilitation of fetal distress, easier suturing compared to that of spontaneous perineal tears, decreased postpartum pelvic organ injury including reduced risk of urinary and anal incontinence, and facilitation of labor in cases of shoulder dystocia. However, the cumulative evidence in the recent decades strongly points to the lack of episiotomy efficiency. Moreover, many studies indicate that episiotomy may be associated with increased maternal morbidity in terms of postpartum bleeding and pain, urinary incontinence and severe perineal tears. Cochrane Collaboration meta-analysis of randomized controlled trials has shown that selective episiotomy significantly decreases the risk of advanced perineal tears (relative risk of 0.67) and the overall need for perineal suturing (relative risk of 0.71), compared to routine episiotomy use. In addition, there is no uniform definition for the indications for episiotomy performance.

In accordance with literature evidence, we hypothesized that avoidance of episiotomy is not associated with increased risk of maternal and neonatal complications, compared to selective episiotomy use. Thus, the objective of our study is to compare maternal and neonatal outcomes in the group with no episiotomy performed to selective episiotomy use.

This randomized controlled clinical trial will be conducted in seven Northern public Israeli Hospitals from February 2015 to February 2019.

The following study protocol was constructed using consultation with experienced epidemiologist and several senior obstetricians.

Women fitting the inclusion criteria will receive a detailed explanation about the trial from one of the approved investigators and will carefully read the relevant forms. In case of agreement for participation in the study, informed consent form will be signed.

Each participant will undergo randomization into two groups:

  1. Control group - in which the decision to perform episiotomy will be based on routine delivery care.
  2. Study group - in which no episiotomy will be performed. Deviation from protocol and episiotomy performance in this group will be allowed only at the discretion of the obstetrician in charge of the delivery, only in cases of unequivocal benefit to the fetus.

The randomization will be carried out using computer software creating random numbers. Allocation to one of the two groups will be done at second stage of labor by opening of sealed opaque envelopes.

Mediolateral or lateral episiotomy (according to the accepted management in each medical center) will be performed during the crowning stage. The incision will be cut at an angle of 45-60º, for 3-4 cm of length.

Epidural anesthesia during labor will be administered in accordance with patient's request. Artificial rupture of membranes, augmentation of the contractions by oxytocin, the decision to perform vacuum extraction or a cesarean birth will be done at the discretion of the attending accoucher, in accordance with the accepted delivery management.

The following data will be obtained for each participant:

  • Demographic and obstetric characteristics, including maternal age, weight, height and race, gestational age and pregnancy complications, clinical and sonographic estimated fetal weight.
  • Delivery and neonatal parameters, including oxytocin use for labor augmentation and epidural anesthesia administration.
  • Primary and secondary outcome measures (described elsewhere).

Sample size calculation was performed by a certified statistician with an extensive experience in clinical trials. It was based on the assumption that the worldwide rate of advanced perineal tears in the control group is 1.6% (according to the latest data reported at the annual Israeli Maternal and Fetal Medicine society meeting at November 2014), and that the rates of these tears in the study group is 1.072% (based on the above mentioned report of Cochrane Collaboration analysis, demonstrating relative risk of 0.67 with selective vs. routine episiotomy use). Given the confidence level of 95% and power of 80%, the required sample size is 14,842 (i.e. 7,421 women in each group).

A year after the trial initiation an interim analysis will be carried out, calculating the up-to-date rate of advanced perineal tears. Sample size will be recalculated based on this rate. In case of statistically significant difference in the primary outcome measure (advanced perineal tears) with a confidence level of 0.003, discontinuation of the trial will be considered due to demonstrated efficacy. Otherwise, the trial will be continued, and the required confidence level at the final statistical calculations will be 0.049.

At the end of data acquisition, statistical analysis will be carried out. Primary and secondary outcome measures will be compared between the two groups. In addition, the association between episiotomy characteristics (incision angle, length and distance from the initiation point to midperineum) to other outcome measures will be assessed.

Statistical analysis will be performed using SPSS software (SPSS Inc., Chicago, IL), in accordance with "intention to treat" concept. Data will be presented to the statistician in a blinded way, as groups "1" and "2", with non-disclosure of the number interpretation. Continuous variables will be presented as mean ± SD and compared using Student's t-test or Mann-Whitney test, as appropriate. Categorical data will be expressed as numbers (percentages) and compared using the Chi square test or Fisher's exact test, when appropriate. Relative risks with 95% confidence intervals will be calculated. A two tailed p<0.05 will be considered statistically significant for all comparisons.

Study Type

Interventional

Enrollment (Actual)

676

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Haifa, Israel
        • Bnai Zion Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Women in labor, or women scheduled for induction of labor, or women attending for a routine follow-up examination during third trimester of pregnancy.
  • First vaginal delivery
  • Singleton pregnancy above 34 gestational weeks
  • Vertex presentation
  • Women who are able to understand and sign the informed consent forms.

Exclusion Criteria:

Absolute contraindications for vaginal delivery (e.g. placenta previa, fetal macrosomia above 4.5 kg, genital herpes)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: No episiotomy
Episiotomy will not be performed in this group. Deviation from protocol (i.e. episiotomy performance) will be allowed only according to the discretion of obstetrician in charge of the delivery, in cases of unequivocal benefit to the fetus.
Avoidance of episiotomy
No Intervention: Selective episiotomy
The decision to perform episiotomy in this group will be based on routine delivery care, i.e. indistinguishable from any other delivery not participating in the trial.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Obstetric Anal Sphincter injury
Time Frame: From the delivery to one hour after delivery
Advanced (3rd and 4th degree) perineal tears, i.e. perineal lacerations involving the anal sphincter, diagnosed by a senior obstetrician
From the delivery to one hour after delivery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
1st and 2nd degree perineal tears
Time Frame: From the delivery to one hour after delivery
1st and 2nd degree perineal tears i.e. lacerations not involving the anal sphincter), diagnosed by an attending accoucher immediately after delivery. Of note, episiotomy will be considered as a 2nd degree tear.
From the delivery to one hour after delivery
Duration of the second stage of labor
Time Frame: From beginning of full dilatation to the delivery of the baby
Time in minutes from full dilatation stage of labor until the delivery of the baby
From beginning of full dilatation to the delivery of the baby
Postpartum hemorrhage
Time Frame: From delivery to one hour postpartum
Excessive vaginal bleeding (above 500 ml according to the subjective evaluation of the attending accoucher, or associated with hemodynamic instability), from the moment of the delivery to one hour after delivery
From delivery to one hour postpartum
Neonatal Apgar score
Time Frame: From the delivery to five minutes after delivery
One and five minutes Apgar scores
From the delivery to five minutes after delivery
Cord blood pH
Time Frame: From the delivery to first two minutes after delivery
Cord blood pH - if measured
From the delivery to first two minutes after delivery
Need of any neonatal resuscitation procedures
Time Frame: From the delivery to one hour after delivery
Any neonatal resuscitation procedures
From the delivery to one hour after delivery
Admission to Neonatal Intensive Care Unit (NICU)
Time Frame: From the delivery to one hour after delivery
Admission to Neonatal Intensive Care Unit (NICU)
From the delivery to one hour after delivery
Shoulder dystocia
Time Frame: From the delivery of the head to the delivery of the shoulders or longer than 60 seconds interval between the delivery of the head to the delivery of the shoulders
The occurrence of shoulder dystocia, defined as a requirement of obstetrical maneuvers for shoulder delivery, or longer than 60 seconds interval between the delivery of the head to the delivery of the shoulders
From the delivery of the head to the delivery of the shoulders or longer than 60 seconds interval between the delivery of the head to the delivery of the shoulders
Episiotomy performance parameters (Indication for episiotomy performance)
Time Frame: During suturing (from the delivery to one hour after the delivery)
Indication for episiotomy performance, incision characteristics - i.e. post-suture angle, length and initiation point of the incision, suturing accoucheur profession (midwife/obstetrician) and duration of his/her obstetric experience.
During suturing (from the delivery to one hour after the delivery)
Characteristics of suturing procedure (The duration of suturing procedure, number of suture packs used during the suturing, subjective grading of suturing difficulty and need for extended suturing in operative room)
Time Frame: During suturing (from the delivery to one hour after the delivery)
The duration of suturing procedure, number of suture packs used during the suturing, subjective grading of suturing difficulty and need for extended suturing in operative room
During suturing (from the delivery to one hour after the delivery)
Postpartum symptoms two days after the delivery (Perineal pain evaluation using 11 points (0-10) Verbal Numeric Scale, urinary retention, perineal infection, perineal hematoma requiring surgical drainage, symptoms of urinary/anal incontinence)
Time Frame: During the second day after the delivery
Perineal pain evaluation using 11 points (0-10) Verbal Numeric Scale, urinary retention (for more than 6 hours after the delivery/urinary catheter extraction), perineal infection, perineal hematoma requiring surgical drainage, symptoms of urinary/anal incontinence
During the second day after the delivery
Phone-call evaluation two months after the delivery
Time Frame: Two months after the delivery
"Yes or no" questions regarding symptoms of urinary/anal incontinence, perineal complications (infection or dehiscence of perineal scar); timing of resumption of sexual activity; perineal pain and dyspareunia evaluation using 11 points (0-10) Verbal Numeric Scale.
Two months after the delivery
Phone-call evaluation one year after the delivery (Two questionnaires)
Time Frame: One year after the delivery
Two questionnaires will be filled: Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12) and Pelvic Floor Distress Inventory-20 (PFDI-20)
One year after the delivery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Shlomi Sagi, M.D., Bnai-Zion Medical Center, Haifa, Israel
  • Principal Investigator: Reuven Keidar, M.D., Carmel Medical Center, Haifa, Israel
  • Principal Investigator: Ido Solt, M.D., Rambam Health Care Campus, Haifa, Israel
  • Principal Investigator: Asnat Walfisch, M.D., Hillel Yaffe medical center, Hadera, Israel
  • Principal Investigator: Dmitry Chuyun, M.D., The BARUCH PADEH Medical Center, Poriya, ISRAEL
  • Principal Investigator: David Peleg, M.D., Ziv Medical Center, Tzfat, Israel
  • Principal Investigator: Oleg Shnaider, M.D., Western Galilee Medical Center, Nahariya, Israel

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2015

Primary Completion (Actual)

May 6, 2018

Study Completion (Actual)

May 6, 2018

Study Registration Dates

First Submitted

February 1, 2015

First Submitted That Met QC Criteria

February 4, 2015

First Posted (Estimate)

February 5, 2015

Study Record Updates

Last Update Posted (Actual)

February 5, 2020

Last Update Submitted That Met QC Criteria

February 2, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 125-14BNZ

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anal Sphincter Injury

Clinical Trials on No episiotomy

3
Subscribe